Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.

A specific plan recognized by all relevant parties could not be formed.

wallstreetcn03:23 ET

Chengfei injection completed, Zhonghang Electronic Measuring Instruments plans to change its name to Zhonghang Chengfei丨Quick Read Announcement.

① Investors have long awaited the integration of Chengfei into Zhonghang Electronic Measuring Instruments, which has finally been completed; ② Zhonghang Electronic Measuring Instruments intends to be renamed as Zhonghang Chengfei.

cls.cn19:43 ET

Analysts predict that ByteDance's AI computing power expenditure will exceed 100 billion yuan by 2025, and the dawn of domestic computing power demand is approaching.

① Recently, ByteDance released a procurement sourcing announcement for the design framework of its self-built Datacenter substation. ② Zheshang Securities stated that the dawn of domestic computing power demand has arrived, and ByteDance has made huge investments in AI, with capital expenditures reaching 80 billion yuan in 2024.

cls.cn18:51 ET

In January, lithium battery companies' production scheduling improved, and the supply-demand relationship is expected to continue to improve after the Spring Festival.

① Recently released data from Shenzhen GaoGong Industry Research Institute indicates that lithium battery companies are expected to adjust their production schedules upwards in January 2025. ② A Research Report from Soochow states that production is expected to rebound rapidly after the Spring Festival, and the supply-demand relationship will continue to improve.

cls.cn18:51 ET

Shandong Hontron Aluminum Industry Holding's restructuring issuance price is at a "discount" of 40%. The stock price hit the daily limit increase on the day before the suspension | Quick read of the announcement.

① The company has set the issuance price for this share issuance to purchase Assets at 5.34 yuan per share; ② This is more than 40% "discount" compared to the price limit increase on the last trading day before the suspension.

cls.cn11:01 ET

Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.

① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.

cls.cnJan 6 10:59 ET